Medscape is available in 5 Language Editions – Choose your Edition here.


Vitamin B-12 Associated Neurological Diseases

  • Author: Niranjan N Singh, MD, DM; Chief Editor: Selim R Benbadis, MD  more...
Updated: Aug 04, 2016


The association of anemia and gastrointestinal and neurologic abnormalities referable to the brain, spinal cord, and peripheral nerves has been recognized in several clinical and postmortem case reports and series by Combe, Addison, and Fenwick since the early 19th century. In 1877, Gardner and Osler coined the term pernicious anemia (PA) to describe a patient with progressive arm numbness and difficulty with buttoning and using tools.[1] Liechtenstein in 1884 reported the association of PA and spinal cord disease but attributed both to tabes dorsalis.[2] Lichtheim in 1887[3] and Minnich in 1892[4] recognized the histologic differences in the spinal cord between PA and tabes dorsalis.

In 1900, Russell et al coined the term subacute combined degeneration of the spinal cord.[5] In 1926, Minot and Murphy fed PA patients a half-pound of calf liver daily, for which they received the Nobel Prize.[6] In 1929, Castle distinguished the role of gastric (intrinsic) and dietary (extrinsic) factors in PA.[7] In 1948, cyanocobalamin was isolated from the liver. The existence of vitamin B-12 deficiency neuropathy was recognized in 1958. In 1955, Lassen et al[8] noted megaloblastic anemia secondary to prolonged nitrous oxide (N2 O) exposure; the neurologic features were described in 1978 by Sahenk et al[9] and Layzer et al.[10]

See the image below.

Vitamin B-12–associated neurological diseases. Per Vitamin B-12–associated neurological diseases. Pernicious anemia. Characteristic lemon-yellow pallor with raw beef tongue lacking filiform papillae. Photo from Forbes and Jackson with permission.

See 21 Hidden Clues to Diagnosing Nutritional Deficiencies, a Critical Images slideshow, to help identify clues to conditions associated with malnutrition.



Vitamin B-12 structure

Vitamin B-12 (cobalamin) is a complex molecule in which a cobalt atom is contained in a corrin ring. Vitamin B-12 is available in animal protein.

Body stores

Total body stores are 2-5 mg, of which half is stored in the liver. The recommended daily intake is 2 mcg/d in adults; pregnant and lactating women require 2.6 mcg/d. Children require 0.7 mcg/d and, in adolescence, 2 mcg/d. Because vitamin B-12 is highly conserved through the enterohepatic circulation, cobalamin deficiency from malabsorption develops after 2-5 years and deficiency from dietary inadequacy in vegetarians develops after 10-20 years. Its causes are mainly nutritional and malabsorptive, PA being most common.

Physiology of absorption

After ingestion, the low stomach pH cleaves cobalamin from other dietary protein.[11] The free cobalamin binds to gastric R binder, a glycoprotein in saliva, and the complex travels to the duodenum and jejunum, where pancreatic peptidases digest the complex and release cobalamin. Free cobalamin can then bind with gastric intrinsic factor (IF), a 50-kd glycoprotein produced by the gastric parietal cells, the secretion of which parallels that of hydrochloric acid. Hence, in states of achlorhydria, IF secretion is reduced, leading to cobalamin deficiency. Importantly, only 99% of ingested cobalamin requires IF for absorption. Up to 1% of free cobalamin is absorbed passively in the terminal ileum. This why oral replacement with large vitamin B-12 doses is appropriate for PA.

Once bound with IF, vitamin B-12 is resistant to further digestion. The complex travels to the distal ileum and binds to a specific mucosal brush border receptor, cublin, which facilitates the internalization of cobalamin-IF complex in an energy-dependent process. Once internalized, IF is removed and cobalamin is transferred to other transport proteins, transcobalamin I, II, and III (TCI, TCII, TCIII). Eighty percent of cobalamin is bound to TCI/III, whose role in cobalamin metabolism is unknown. The other 20% binds with TCII, the physiologic transport protein produced by endothelial cells. Its half-life is 6-9 min, thus delivery to target tissues is rapid.

The cobalamin-TCII complex is secreted into the portal blood where it is taken up mainly in the liver and bone marrow as well as other tissues. Once in the cytoplasm, cobalamin is liberated from the complex by lysosomal degradation. An enzyme-mediated reduction of the cobalt occurs by cytoplasmic methylation to form methylcobalamin or by mitochondrial adenosylation to form adenosylcobalamin, the 2 metabolically active forms of cobalamin.

Vitamin B-12 role in bone marrow function

In the cytoplasm, methylcobalamin (see image below) serves as cofactor for methionine synthesis by allowing transfer of a methyl group from 5-methyl-tetrahydrofolate (5-methyl-THF) to homocysteine (HC), forming methionine and demethylated tetrahydrofolate (THF). This results in reduction in serum homocysteine, which appears to be toxic to endothelial cells. Methionine is further metabolized to S-adenosylmethionine (SAM).

Vitamin B-12–associated neurological diseases. Cob Vitamin B-12–associated neurological diseases. Cobalamin and folate metabolism. TS = thymidylate synthase, DHFR = dihydrofolate reductase, SHMT = serine methyl-transferase.

THF is used for DNA synthesis. After conversion to its polyglutamate form, THF participates in purine synthesis and the conversion of deoxyuridylate (dUTP) to deoxythymidine monophosphate (dTMP), which is then phosphorylated to deoxythymidine triphosphate (dTTP). dTTP is required for DNA synthesis; therefore, in vitamin B-12 deficiency, formation of dTTP and accumulation of 5-methyl-THF is inadequate, trapping folate in its unusable form and leading to retarded DNA synthesis. RNA contains dUTP (deoxyuracil triphosphate) instead of dTTP, allowing for protein synthesis to proceed uninterrupted and resulting in macrocytosis and cytonuclear dissociation.

Because folate deficiency causes macrocytosis and cytonuclear dissociation via the same mechanisms, both deficiencies lead to megaloblastic anemia and disordered maturation in granulocytic lineages; therefore, folate supplementation can reverse the hematologic abnormalities of vitamin B-12 deficiency but has no impact on the neurologic abnormalities of vitamin B-12 deficiency, indicating both result from different mechanisms.

Vitamin B-12 role in the peripheral and central nervous systems

The neurologic manifestation of cobalamin deficiency is less well understood. CNS demyelination may play a role, but how cobalamin deficiency leads to demyelination remains unclear. Reduced SAM or elevated methylmalonic acid (MMA) may be involved.

SAM is required as the methyl donor in polyamine synthesis and transmethylation reactions. Methylation reactions are needed for myelin maintenance and synthesis. SAM deficiency results in abnormal methylated phospholipids such as phosphatidylcholine, and it is linked to central myelin defects and abnormal neuronal conduction, which may account for the encephalopathy and myelopathy. In addition, SAM influences serotonin, norepinephrine, and dopamine synthesis. This suggests that, in addition to structural consequences of vitamin B-12 deficiency, functional effects on neurotransmitter synthesis that may be relevant to mental status changes may occur. Parenthetically, SAM is being studied as a potential antidepressant.

Another possible cause of neurologic manifestations involves the other metabolically active form of cobalamin, adenosylcobalamin (see image below), a mitochondrial cofactor in the conversion of L-methylmalonyl CoA to succinyl CoA. Vitamin B-12 deficiency leads to an increase in L-methylmalonyl-CoA, which is converted to D-methylmalonyl CoA and hydrolyzed to MMA. Elevated MMA results in abnormal odd chain and branched chain fatty acids with subsequent abnormal myelination, possibly leading to defective nerve transmission.

Vitamin B-12–associated neurological diseases. Cob Vitamin B-12–associated neurological diseases. Cobalamin deficiency leads to reduced adenosylcobalamin, which is required for production of succinyl-CoA. D-methylmalonyl-CoA is converted to methylmalonic acid.

More recent studies propose a very different paradigm: B-12 and its deficiency impact a network of cytokines and growth factors, ie, brain, spinal cord, and CSF TNF-alpha; nerve growth factor (NGF), IL-6 and epidermal growth factor (EGF), some of which are neurotrophic, others neurotoxic. Vitamin B-12 regulates IL-6 levels in rodent CSF. In rodent models of B-12 deficiency parenteral EGF or anti-NGF antibody injection prevents, like B-12 itself, the SCD-like lesions.

In the same models, the mRNAs of several cell-type specific proteins (glial fibrillary acidic protein, myelin basic protein) are decreased in a region specific manner in the CNS, but, in the PNS myelin, protein zero and peripheral myelin protein 22 mRNA remain unaltered.

In human and rodent serum and CSF, concomitantly with a vitamin B-12 decrease, EGF levels are decreased, while at the same time, TNF-alpha increases in step with homocysteine levels. These observations provide evidence that the clinical and histological changes of vitamin B-12 deficiency may result from up-regulation of neurotoxic cytokines and down-regulation of neurotrophic factors.[12]


N2 O can oxidize the cobalt core of vitamin B-12 from a 1+ to 3+ valance state, rendering methylcobalamin inactive, inhibiting HC conversion to methionine and depleting the supply of SAM. Patients with sufficient vitamin B-12 body stores can maintain cellular functions after N2 O exposure, but in patients with borderline or low vitamin B-12 stores, this oxidation may be sufficient to precipitate clinical manifestations.




The prevalence of vitamin B-12 deficiency is difficult to ascertain because of diverse etiologies and different assays (i.e., radioassay or chemiluminescence). Affected individuals may number 300,000 to 3 million in the United States.

Using the radioassay and a value less than 200 pg/mL, the prevalence of vitamin B-12 deficiency is 3-16%. In a geriatric population using a radioassay cutoff of 300 pg/mL and elevated HC and MMA levels, a prevalence of 21% was reported.

Of HIV-seropositive individuals, 11% are vitamin B-12 deficient; another 12% have levels of 200-240 pg/mL. In a subgroup with chronic diarrhea, the rate reaches 39%. However, the importance for vitamin B-12 deficiency in the development of neurologic disease in these patients remains unclear.

In Europe, the prevalence of vitamin B-12 deficiency is 1.6-10%.

In India, a hospital population radioassay study with a cutoff of 200 pg/mL found a vitamin B-12 deficiency in 0.88% of patients, with borderline values in 3.8%.


See the list below:

  • Vitamin B-12 deficiency is associated with an elevated HC.
  • The prevalence of hyperhomocysteinemia in the general population is 5-10%; in people older than 65 years it may reach 30-40%. Elevated HC is a risk factor for coronary artery, cerebrovascular, and peripheral vascular diseases and venous thrombosis. About 10% of the vascular disease risk in the general population is linked to HC.
  • Case-control studies have reported a correlation between multi-infarct dementia or dementia of the Alzheimer type and elevated HC; vitamin B-12 supplementation had no clinical benefit.
  • Neural tube defects are associated with low folate and vitamin B-12.
  • PA patients have a 3 times and 13 times increased risk of gastric carcinoma and gastric carcinoid tumors, respectively.
  • Patients with diabetes mellitus type 1 and autoimmune thyroid diseases are at higher risk of developing PA. A 2009 study noted a 22% prevalence of vitamin B-12 deficiency in patients with diabetes mellitus type 2. [13]
  • Multifactorial abnormalities of vitamin B-12 metabolism and absorption occur in HIV infection.


See the list below:

  • PA prevalence may be higher in white people and lower in Hispanic and black people.
  • No known relationship exists between neurologic symptoms and race.
  • Studies in Africa and the United States have shown higher vitamin B-12 and transcobalamin II levels in black than in white individuals. Additionally, blacks have lower HC levels and metabolize it more efficiently than whites.


See the list below:

  • In Europe and Africa, the prevalence of PA is higher in elderly women than men (1.5:1), while in the United States no differences exist.
  • Men have higher HC levels at all ages.
  • Pregnancy and estrogen replacement in postmenopausal women lower HC levels.


See the list below:

  • PA occurs in people of all ages, but it is more common in people older than 40-70 years and, in particular, in people older than 65 years.
  • In white people, the mean age of onset is 60; in black people, the mean age is 50 years.
  • Congenital PA manifests in children aged 9 months to 10 years; the mean age is 2 years.
Contributor Information and Disclosures

Niranjan N Singh, MD, DM Associate Professor of Neurology, University of Missouri-Columbia School of Medicine

Niranjan N Singh, MD, DM is a member of the following medical societies: American Academy of Neurology, American Association of Neuromuscular and Electrodiagnostic Medicine, American Headache Society

Disclosure: Nothing to disclose.


Florian P Thomas, MD, PhD, Drmed, MA, MS Director, National MS Society Multiple Sclerosis Center; Professor and Director, Clinical Research Unit, Department of Neurology, Adjunct Professor of Physical Therapy, Associate Professor, Institute for Molecular Virology, St Louis University School of Medicine; Editor-in-Chief, Journal of Spinal Cord Medicine

Florian P Thomas, MD, PhD, Drmed, MA, MS is a member of the following medical societies: Academy of Spinal Cord Injury Professionals, American Academy of Neurology, American Neurological Association, Consortium of Multiple Sclerosis Centers, National Multiple Sclerosis Society, Sigma Xi

Disclosure: Nothing to disclose.

Alan L Diamond, DO Movement Disorder Fellow, Department of Neurology, Baylor College of Medicine

Alan L Diamond, DO is a member of the following medical societies: American Academy of Neurology, American Medical Association, American Osteopathic Association, American Society of Neuroimaging

Disclosure: Nothing to disclose.

Specialty Editor Board

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Received salary from Medscape for employment. for: Medscape.

Nestor Galvez-Jimenez, MD, MSc, MHA The Pauline M Braathen Endowed Chair in Neurology, Chairman, Department of Neurology, Program Director, Movement Disorders, Department of Neurology, Division of Medicine, Cleveland Clinic Florida

Nestor Galvez-Jimenez, MD, MSc, MHA is a member of the following medical societies: American Academy of Neurology, American College of Physicians, International Parkinson and Movement Disorder Society

Disclosure: Nothing to disclose.

Chief Editor

Selim R Benbadis, MD Professor, Director of Comprehensive Epilepsy Program, Departments of Neurology and Neurosurgery, Tampa General Hospital, University of South Florida Morsani College of Medicine

Selim R Benbadis, MD is a member of the following medical societies: American Academy of Neurology, American Academy of Sleep Medicine, American Clinical Neurophysiology Society, American Epilepsy Society, American Medical Association

Disclosure: Serve(d) as a director, officer, partner, employee, advisor, consultant or trustee for: Cyberonics; Eisai; Lundbeck; Sunovion; UCB; Upsher-Smith<br/>Serve(d) as a speaker or a member of a speakers bureau for: Cyberonics (Livanova); Eisai; Lundbeck; Sunovion; UCB<br/>Received research grant from: Cyberonics (Livanova); GW, Lundbeck; Sunovion; UCB; Upsher-Smith.

Additional Contributors

Christopher Luzzio, MD Clinical Assistant Professor, Department of Neurology, University of Wisconsin at Madison School of Medicine and Public Health

Christopher Luzzio, MD is a member of the following medical societies: American Academy of Neurology

Disclosure: Nothing to disclose.

  1. Gardner W, Osler W. A case of progressive pernicious anemia (Idiopathic of Addison). Can Med Surg J. 1877. 5:385-404.

  2. Leichtenstein O. Uber progressive perniciose anamie bei tabeskranken. Deutsche Medizinische Wochenschrift. 1884. 10:849.

  3. Lichtheim L. Zur kenntniss der perniziosen anamie. Muchen. Schweiz med wochenschr. 1887. 34:300.

  4. Minnich W. Kenntnis der im Verlaufe der perniciosen anamie beobachteten spinalerkrankungen. Zeitschrift fur Klinische Medizin. 1892. 21:264-314.

  5. Russell JSR, Batten FE, Collier J. Subacute combined degeneration of the spinal cord. Brain. 1900. 23:39.

  6. Minot GR, Murphy WP. Treatment of pernicious anemia by a special diet. JAMA. 1926. 87:470-476.

  7. Castle WB. Extrinsic factor in pernicious anemia. American Journal of Medical Science. 1929. 178:148.

  8. Lassen HCA, Henricksen E, Neukirch F. Treatment of tetanus: severe bone marrow depression after prolonged nitrous oxide anesthesia. Lancet. 1956. 1:527-530.

  9. Sahenk Z, Mendell JR, Couri D. Polyneuropathy from inhalation of N2O cartridges through a whipped-cream dispenser. Neurology. 1978 May. 28(5):485-7. [Medline].

  10. Layzer RB. Myeloneuropathy after prolonged exposure to nitrous oxide. Lancet. 1978 Dec 9. 2(8102):1227-30. [Medline].

  11. Nielsen MJ, Rasmussen MR, Andersen CB, Nexø E, Moestrup SK. Vitamin B12 transport from food to the body's cells--a sophisticated, multistep pathway. Nat Rev Gastroenterol Hepatol. 2012 May 1. 9(6):345-54. [Medline].

  12. Leishear K, Ferrucci L, Lauretani F, Boudreau RM, Studenski SA, Rosano C, et al. Vitamin B12 and homocysteine levels and 6-year change in peripheral nerve function and neurological signs. J Gerontol A Biol Sci Med Sci. 2012 May. 67(5):537-43. [Medline]. [Full Text].

  13. Pflipsen MC, Oh RC, Saguil A, Seehusen DA, Topolski R. The prevalence of vitamin B(12) deficiency in patients with type 2 diabetes: a cross-sectional study. J Am Board Fam Med. 2009 Sep-Oct. 22(5):528-34. [Medline].

  14. Nachum-Biala Y, Troen AM. B-vitamins for neuroprotection: narrowing the evidence gap. Biofactors. 2012 Mar-Apr. 38(2):145-50. [Medline].

  15. Leishear K, Ferrucci L, Lauretani F, Boudreau RM, Studenski SA, Rosano C, et al. Vitamin B12 and homocysteine levels and 6-year change in peripheral nerve function and neurological signs. J Gerontol A Biol Sci Med Sci. 2012 May. 67(5):537-43. [Medline]. [Full Text].

  16. Misra UK, Kalita J. Comparison of clinical and electrodiagnostic features in B12 deficiency neurological syndromes with and without antiparietal cell antibodies. Postgrad Med J. 2007 Feb. 83(976):124-7. [Medline].

  17. Schilling RF. Is nitrous oxide a dangerous anesthetic for vitamin B12-deficient subjects?. JAMA. 1986 Mar 28. 255(12):1605-6. [Medline].

  18. Kinsella LJ, Green R. Anesthesia paresthetica': nitrous oxide-induced cobalamin deficiency. Neurology. 1995 Aug. 45(8):1608-10. [Medline].

  19. Healton EB, Savage DG, Brust JC. Neurologic aspects of cobalamin deficiency. Medicine (Baltimore). 1991 Jul. 70(4):229-45. [Medline].

  20. Woltmann HW. The nervous symptoms in pernicious anemia: an analysis of one hundred and fifty cases. American Journal of Medical Science. 1919. 173:400-9.

  21. Dynes JB, Norcross JW. Peripheral neuritis as a complication of pernicious anemia. JAMA. 1943. 122:586-8.

  22. Steiner I, Kidron D, Soffer D. Sensory peripheral neuropathy of vitamin B12 deficiency: a primary demyelinating disease?. J Neurol. 1988 Jan. 235(3):163-4. [Medline].

  23. Greenfield JG. Subacute spinocerebellar degeneration occurring in elderly patients. Brain. 1934. 57:161-76.

  24. McCombe PA, McLeod JG. The peripheral neuropathy of vitamin B12 deficiency. J Neurol Sci. 1984 Oct. 66(1):117-26. [Medline].

  25. Coers C, Woolf AL. The Innervation of Muscle. Oxford, England: Blackwell Scientific; 1959. 91.

  26. Dalla Torre C, Lucchetta M, Cacciavillani M, Campagnolo M, Manara R, Briani C. Reversible isolated sensory axonal neuropathy due to cobalamin deficiency. Muscle Nerve. 2012 Mar. 45(3):428-30. [Medline].

  27. van Loon M, Postels DG, Heikens GT, Molyneux E. Severe pernicious anaemia in an 8-year-old African girl. Ann Trop Paediatr. 2009 Sep. 29(3):231-4. [Medline].

  28. Lahner E, Annibale B. Pernicious anemia: new insights from a gastroenterological point of view. World J Gastroenterol. 2009 Nov 7. 15(41):5121-8. [Medline]. [Full Text].

  29. Vasconcelos OM, Poehm EH, McCarter RJ, Campbell WW, Quezado ZM. Potential outcome factors in subacute combined degeneration: review of observational studies. J Gen Intern Med. Oct 2006. 21(10):1063-8. [Medline].

  30. Adachi H, Hirai Y, Fujiura Y. Plasma homocysteine levels and atherosclerosis in Japan: epidemiological study by use of carotid ultrasonography. Stroke. 2002 Sep. 33(9):2177-81. [Medline].

  31. Addison T. Anemia: Disease of the suprarenal capsules. London Med Gazette. 1849. 8:517-518.

  32. Al-Shubaili AF, Farah SA, Hussein JM, et al. Axonal and demyelinating neuropathy with reversible proximal conduction block, an unusual feature of vitamin B12 deficiency. Muscle Nerve. 1998 Oct. 21(10):1341-3. [Medline].

  33. Allen RH, Stabler SP, Savage DG. Metabolic abnormalities in cobalamin (vitamin B12) and folate deficiency. FASEB J. 1993 Nov. 7(14):1344-53. [Medline].

  34. Andres E, Noel E, Kaltenbach G. [Vitamin B12 deficiency with normal Schilling test or non-dissociation of vitamin B12 and its carrier proteins in elderly patients. A study of 60 patients]. Rev Med Interne. 2003 Apr. 24(4):218-23. [Medline].

  35. Baik HW, Russell RM. Vitamin B12 deficiency in the elderly. Annu Rev Nutr. 1999. 19:357-77. [Medline].

  36. Balducci L. Epidemiology of anemia in the elderly: information on diagnostic evaluation. J Am Geriatr Soc. 2003 Mar. 51(3 Suppl):S2-9. [Medline].

  37. Beach RS, Mantero-Atienza E, Shor-Posner G. Specific nutrient abnormalities in asymptomatic HIV-1 infection. AIDS. 1992 Jul. 6(7):701-8. [Medline].

  38. Berger JR, Quencer R. Reversible myelopathy with pernicious anemia: clinical/MR correlation. Neurology. 1991 Jun. 41(6):947-8. [Medline].

  39. Booth GL, Wang EE. Preventive health care, 2000 update: screening and management of hyperhomocysteinemia for the prevention of coronary artery disease events. The Canadian Task Force on Preventive Health Care. CMAJ. 2000 Jul 11. 163(1):21-9. [Medline].

  40. Boushey CJ, Beresford SA, Omenn GS, Motulsky AG. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. JAMA. 1995 Oct 4. 274(13):1049-57. [Medline].

  41. Carmel R. Prevalence of undiagnosed pernicious anemia in the elderly. Arch Intern Med. 1996 May 27. 156(10):1097-100. [Medline].

  42. Carmel R. Reassessment of the relative prevalences of antibodies to gastric parietal cell and to intrinsic factor in patients with pernicious anaemia: influence of patient age and race. Clin Exp Immunol. 1992 Jul. 89(1):74-7. [Medline].

  43. Carmel R, Gott PS, Waters CH. The frequently low cobalamin levels in dementia usually signify treatable metabolic, neurologic and electrophysiologic abnormalities. Eur J Haematol. 1995 Apr. 54(4):245-53. [Medline].

  44. Carmel R, Johnson CS. Racial patterns in pernicious anemia. Early age at onset and increased frequency of intrinsic-factor antibody in black women. N Engl J Med. 1978 Mar 23. 298(12):647-50. [Medline].

  45. Carmel R, Johnson CS, Weiner JM. Pernicious anemia in Latin Americans is not a disease of the elderly. Arch Intern Med. 1987 Nov. 147(11):1995-6. [Medline].

  46. Chanarin I. The Megaloblastic Anemias. 2nd ed. Oxford, England: Blackwell Scientific; 1979.

  47. Clarke R, Smith AD, Jobst KA, et al. Folate, vitamin B12, and serum total homocysteine levels in confirmed Alzheimer disease. Arch Neurol. 1998 Nov. 55(11):1449-55. [Medline].

  48. Cole M. Neurological manifestation of vitamin B12 deficiency. Goetz C, Aminoff M, eds. Handbook of Clinical Neurology. Vol 26. Systemic Diseases. Part II. Amsterdam, Holland: Elsevier Science BV; 1998: 367-405.

  49. Combe JJ. History of a case of anemia. Trans Med Chir Soc Edimb. 1822. 1:194-204.

  50. Cunha UG, Rocha FL, Peixoto JM. Vitamin B12 deficiency and dementia. Int Psychogeriatr. 1995 Spring. 7(1):85-8. [Medline].

  51. Daly LE, Kirke PN, Molloy A, et al. Folate levels and neural tube defects. Implications for prevention. JAMA. 1995 Dec 6. 274(21):1698-702. [Medline].

  52. Dana CL. Subacute combined sclerosis of the spinal cord and its relation to anemia and to toxemia. J Nerv Ment Dis. 1899. 26:1.

  53. Diaz-Arrastia R. Homocysteine and neurologic disease. Arch Neurol. 2000 Oct. 57(10):1422-7. [Medline].

  54. Ehrenpreis ED, Carlson SJ, Boorstein HL. Malabsorption and deficiency of vitamin B12 in HIV-infected patients with chronic diarrhea. Dig Dis Sci. 1994 Oct. 39(10):2159-62. [Medline].

  55. Fenwick S. On atrophy of the stomach. Lancet. 1870. ii:78-80.

  56. Fine EJ, Hallett M. Neurophysiological study of subacute combined degeneration. J Neurol Sci. 1980 Mar. 45(2-3):331-6. [Medline].

  57. Fine EJ, Soria E, Paroski MW. The neurophysiological profile of vitamin B12 deficiency. Muscle Nerve. 1990 Feb. 13(2):158-64. [Medline].

  58. Fowler B. Genetic defects of folate and cobalamin metabolism. Eur J Pediatr. 1998 Apr. 157 Suppl 2:S60-6. [Medline].

  59. Goodman BP, Chong BW, Patel AC, Fletcher GP, Smith BE. Copper deficiency myeloneuropathy resembling B12 deficiency: partial resolution of MR imaging findings with copper supplementation. AJNR Am J Neuroradiol. 2006 Nov-Dec. 27(10):2112-4. [Medline].

  60. Graham D, Lantos P. Vitamin Deficiencies. In: Greenfield's Neuropathology. 6th ed. London, England:. Arnold Publishers. 1997:621-624.

  61. Grattan-Smith PJ, Wilcken B, Procopis PG. The neurological syndrome of infantile cobalamin deficiency: developmental regression and involuntary movements. Mov Disord. 1997 Jan. 12(1):39-46. [Medline].

  62. Green R, Kinsella LJ. Current concepts in the diagnosis of cobalamin deficiency. Neurology. 1995 Aug. 45(8):1435-40. [Medline].

  63. Greenfield JG, Carmichael EA. Peripheral nerves in cases of subacute combined degeneration of the cord. Brain. 1935. 58:483-91.

  64. Gueant JL, Saunier M, Gastin I. Decreased activity of intestinal and urinary intrinsic factor receptor in Grasbeck-Imerslund disease [corrected]. Gastroenterology. 1995 Jun. 108(6):1622-8. [Medline].

  65. Hamilton AS, Nixon CE. Sensory changes in the subacute combined degeneration of pernicious anemia. Arch Neurol Psychiatry. 1921. 6:1.

  66. Hemmer B, Glocker FX, Schumacher M, et al. Subacute combined degeneration: clinical, electrophysiological, and magnetic resonance imaging findings. J Neurol Neurosurg Psychiatry. 1998 Dec. 65(6):822-7. [Medline].

  67. Hennerici M. Dissociated foveal and parafoveal visual evoked responses in subacute combined degeneration. Arch Neurol. 1985 Feb. 42(2):130-2. [Medline].

  68. Hsing AW, Hansson LE, McLaughlin JK, et al. Pernicious anemia and subsequent cancer. A population-based cohort study. Cancer. 1993 Feb 1. 71(3):745-50. [Medline].

  69. Hutto BR. Folate and cobalamin in psychiatric illness. Compr Psychiatry. 1997 Nov-Dec. 38(6):305-14. [Medline].

  70. Jacques PF, Rosenberg IH, Rogers G, et al. Serum total homocysteine concentrations in adolescent and adult Americans: results from the third National Health and Nutrition Examination Survey. Am J Clin Nutr. 1999 Mar. 69(3):482-9. [Medline].

  71. Janson JJ, Galarza CR, Murua A. Prevalence of hyperhomocysteinemia in an elderly population. Am J Hypertens. 2002 May. 15(5):394-7. [Medline].

  72. Kagan BL, Sultzer DL, Rosenlicht N. Oral S-adenosylmethionine in depression: a randomized, double-blind, placebo-controlled trial. Am J Psychiatry. 1990 May. 147(5):591-5. [Medline].

  73. Kang SS, Wong PW, Zhou JM, Cook HY. Total homocyst(e)ine in plasma and amniotic fluid of pregnant women. Metabolism. 1986 Oct. 35(10):889-91. [Medline].

  74. Kapadia CR. Vitamin B12 in health and disease: part I--inherited disorders of function, absorption, and transport. Gastroenterologist. 1995 Dec. 3(4):329-44. [Medline].

  75. Kaptan K, Beyan C, Ural AU. Helicobacter pylori--is it a novel causative agent in Vitamin B12 deficiency?. Arch Intern Med. 2000 May 8. 160(9):1349-53. [Medline].

  76. Karlsson FA, Burman P, Loof L. Enzyme-linked immunosorbent assay of H+,K+-ATPase, the parietal cell antigen. Clin Exp Immunol. 1987 Dec. 70(3):604-10. [Medline].

  77. Karnaze DS, Carmel R. Neurologic and evoked potential abnormalities in subtle cobalamin deficiency states, including deficiency without anemia and with normal absorption of free cobalamin. Arch Neurol. 1990 Sep. 47(9):1008-12. [Medline].

  78. Katsaros VK, Glocker FX, Hemmer B, Schumacher M. MRI of spinal cord and brain lesions in subacute combined degeneration. Neuroradiology. 1998 Nov. 40(11):716-9. [Medline].

  79. Kieburtz KD, Giang DW, Schiffer RB, Vakil N. Abnormal vitamin B12 metabolism in human immunodeficiency virus infection. Association with neurological dysfunction. Arch Neurol. 1991 Mar. 48(3):312-4. [Medline].

  80. Kirke PN, Molloy AM, Daly LE. Maternal plasma folate and vitamin B12 are independent risk factors for neural tube defects. Q J Med. 1993 Nov. 86(11):703-8. [Medline].

  81. Krumholz A, Weiss HD, Goldstein PJ, Harris KC. Evoked responses in vitamin B12 deficiency. Ann Neurol. 1981 Apr. 9(4):407-9. [Medline].

  82. Larner AJ, Zeman AZ, Allen CM. MRI appearances in subacute combined degeneration of the spinal cord due to vitamin B12 deficiency. J Neurol Neurosurg Psychiatry. 1997 Jan. 62(1):99-100. [Medline].

  83. Lehmann M, Gottfries CG, Regland B. Identification of cognitive impairment in the elderly: homocysteine is an early marker. Dement Geriatr Cogn Disord. 1999 Jan-Feb. 10(1):12-20. [Medline].

  84. Lester-Smith E. Purification of antipernicious amaemia factors from liver. Nature. 1948. 161:638-639.

  85. Lindenbaum J, Rosenberg IH, Wilson PW, et al. Prevalence of cobalamin deficiency in the Framingham elderly population. Am J Clin Nutr. 1994 Jul. 60(1):2-11. [Medline].

  86. Lindenbaum J, Savage DG, Stabler SP. Diagnosis of cobalamin deficiency: II. Relative sensitivities of serum cobalamin, methylmalonic acid, and total homocysteine concentrations. Am J Hematol. 1990 Jun. 34(2):99-107. [Medline].

  87. Magnaghi V, Veber D, Morabito A. Decreased GFAP-mRNA expression in spinal cord of cobalamin-deficient rats. FASEB J. 2002. 16:1820-1822. [Medline].

  88. Marie RM, Le Biez E, Busson P, et al. Nitrous oxide anesthesia-associated myelopathy. Arch Neurol. 2000 Mar. 57(3):380-2. [Medline].

  89. Metz J. Cobalamin deficiency and the pathogenesis of nervous system disease. Annu Rev Nutr. 1992. 12:59-79. [Medline].

  90. Metz J. Pathogenesis of cobalamin neuropathy: deficiency of nervous system S-adenosylmethionine?. Nutr Rev. 1993 Jan. 51(1):12-5. [Medline].

  91. Ozer EA, Turker M, Bakiler AR. Involuntary movements in infantile cobalamin deficiency appearing after treatment. Pediatr Neurol. 2001 Jul. 25(1):81-3. [Medline].

  92. Paltiel O, Falutz J, Veilleux M. Clinical correlates of subnormal vitamin B12 levels in patients infected with the human immunodeficiency virus. Am J Hematol. 1995 Aug. 49(4):318-22. [Medline].

  93. Pant SS, Asbury AK, Richardson EP Jr. The myelopathy of pernicious anemia. A neuropathological reappraisal. Acta Neurol Scand. 1968. 44:Suppl 5:1-36. [Medline].

  94. Penix LP. Ischemic strokes secondary to vitamin B12 deficiency-induced hyperhomocystinemia. Neurology. 1998 Aug. 51(2):622-4. [Medline].

  95. Perros P, Singh RK, Ludlam CA, Frier BM. Prevalence of pernicious anaemia in patients with Type 1 diabetes mellitus and autoimmune thyroid disease. Diabet Med. 2000 Oct. 17(10):749-51. [Medline].

  96. Platica O, Janeczko R, Quadros EV. The cDNA sequence and the deduced amino acid sequence of human transcobalamin II show homology with rat intrinsic factor and human transcobalamin I. J Biol Chem. 1991 Apr 25. 266(12):7860-3. [Medline].

  97. Postiglione A, Milan G, Ruocco A. Plasma folate, vitamin B(12), and total homocysteine and homozygosity for the C677T mutation of the 5,10-methylene tetrahydrofolate reductase gene in patients with Alzheimer''s dementia. A case-control study. Gerontology. 2001 Nov-Dec. 47(6):324-9. [Medline].

  98. Pruthi RK, Tefferi A. Pernicious anemia revisited. Mayo Clin Proc. 1994 Feb. 69(2):144-50. [Medline].

  99. Putnam JJ. A group of cases of systemic scleroses of the spinal cord, associated with diffuse collateral degeneration, occurring in enfeebled persons past middle life, especially in women: Studied with particular reference to etiology. J Nerv Ment Dis. 1891. 16:69.

  100. Remacha AF, Cadafalch J. Cobalamin deficiency in patients infected with the human immunodeficiency virus. Semin Hematol. 1999 Jan. 36(1):75-87. [Medline].

  101. Renault F, Verstichel P, Ploussard JP. Neuropathy in two cobalamin-deficient breast-fed infants of vegetarian mothers. Muscle Nerve. 1999 Feb. 22(2):252-4. [Medline].

  102. Richmond J, Davidson S. Subacute combined degeneration of the spinal cord in non-Addisonian megaloblastic anaemia. Quarterly Journal of Medicine. 1958. 27:517-531.

  103. Rickes EL, Brink NG, Koniuszy FR. Crystalline vitamin B 12. Science. 1948. 107:396.

  104. Robertson KR, Stern RA, Hall CD. Vitamin B12 deficiency and nervous system disease in HIV infection. Arch Neurol. 1993 Aug. 50(8):807-11. [Medline].

  105. Sacco RL, Roberts JK, Jacobs BS. Homocysteine as a risk factor for ischemic stroke: an epidemiological story in evolution. Neuroepidemiology. 1998. 17(4):167-73. [Medline].

  106. Savage DG, Lindenbaum J. Neurological complications of acquired cobalamin deficiency: clinical aspects. Baillieres Clin Haematol. 1995 Sep. 8(3):657-78. [Medline].

  107. Savage DG, Lindenbaum J, Stabler SP. Sensitivity of serum methylmalonic acid and total homocysteine determinations for diagnosing cobalamin and folate deficiencies. Am J Med. 1994 Mar. 96(3):239-46. [Medline].

  108. Scalabrino G, Carpo M, Bamonti F. High tumor necrosis factor-alpha [corrected] levels in cerebrospinal fluid of cobalamin-deficient patients. Ann Neurol. 2004. 56:886-890. [Medline].

  109. Scalabrino G, Corsi MM, Veber D. Cobalamin (vitamin B(12)) positively regulates interleukin-6 levels in rat cerebrospinal fluid. J Neuroimmunol. 2002. 127:37-43. [Medline].

  110. Scalabrino G, Mutti E, Veber D. Increased spinal cord NGF levels in rats with cobalamin (vitamin B12) deficiency. Neurosci Lett. 2006 Mar 27. 396(2):153-8. [Medline].

  111. Scott E. The prevalence of pernicious anemia in Britain. J Coll Gen Pract Res News. 1960. 3:80-4.

  112. Scott JM. Folate and vitamin B12. Proc Nutr Soc. 1999 May. 58(2):441-8. [Medline].

  113. Selhub J, D'Angelo A. Hyperhomocysteinemia and thrombosis: acquired conditions. Thromb Haemost. 1997 Jul. 78(1):527-31. [Medline].

  114. Stabler SP, Allen RH, Fried LP, et al. Racial differences in prevalence of cobalamin and folate deficiencies in disabled elderly women. Am J Clin Nutr. 1999 Nov. 70(5):911-9. [Medline].

  115. Stabler SP, Allen RH, Savage DG. Clinical spectrum and diagnosis of cobalamin deficiency. Blood. 1990 Sep 1. 76(5):871-81. [Medline].

  116. Stacy CB, Di Rocco A, Gould RJ. Methionine in the treatment of nitrous-oxide-induced neuropathy and myeloneuropathy. J Neurol. 1992 Aug. 239(7):401-3. [Medline].

  117. Sumner AE, Chin MM, Abrahm JL, et al. Elevated methylmalonic acid and total homocysteine levels show high prevalence of vitamin B12 deficiency after gastric surgery. Ann Intern Med. 1996 Mar 1. 124(5):469-76. [Medline].

  118. Surtees R. Biochemical pathogenesis of subacute combined degeneration of the spinal cord and brain. J Inherit Metab Dis. 1993. 16(4):762-70. [Medline].

  119. Tan SV, Guiloff RJ. Hypothesis on the pathogenesis of vacuolar myelopathy, dementia, and peripheral neuropathy in AIDS. J Neurol Neurosurg Psychiatry. 1998 Jul. 65(1):23-8. [Medline].

  120. Tefferi A, Pruthi RK. The biochemical basis of cobalamin deficiency. Mayo Clin Proc. 1994 Feb. 69(2):181-6. [Medline].

  121. Toh BH, van Driel IR, Gleeson PA. Pernicious anemia. N Engl J Med. 1997 Nov 13. 337(20):1441-8. [Medline].

  122. Tracey JP, Schiffman FJ. Magnetic resonance imaging in cobalamin deficiency. Lancet. 1992 May 9. 339(8802):1172-3. [Medline].

  123. Van der Mooren MJ, Wouters MG, Blom HJ, et al. Hormone replacement therapy may reduce high serum homocysteine in postmenopausal women. Eur J Clin Invest. 24(11):733-6. [Medline].

  124. Victor M. Polyneuropathy due to nutritional deficiency and alcoholism. Dyck PJ, Thomas PK, Lambert EH, eds. Peripheral Neuropathy. Philadelphia, Pa: WB Saunders; 1975: 1030.

  125. Wadia RS, Bandishti S, Kharche M. B12 and folate deficiency: incidence and clinical features. Neurol India. 2000 Dec. 48(4):302-4. [Medline].

  126. Wang HX, Wahlin A, Basun H. Vitamin B(12) and folate in relation to the development of Alzheimer''s disease. Neurology. 2001 May 8. 56(9):1188-94. [Medline].

  127. Weir DG, Scott JM. Brain function in the elderly: role of vitamin B12 and folate. Br Med Bull. 1999. 55(3):669-82. [Medline].

  128. Wilhelm H, Grodd W, Schiefer U. Uncommon chiasmal lesions: demyelinating disease, vasculitis, and cobalamin deficiency. Ger J Ophthalmol. 1993. 2(4-5):234-40. [Medline].

  129. Wright JD, Bialostosky K, Gunter EW, et al. Blood folate and vitamin B12: United States, 1988-94. Vital Health Stat 11. 1998 Dec. (243):1-78. [Medline].

  130. Yao Y, Yao SL, Yao SS. Prevalence of vitamin B12 deficiency among geriatric outpatients. J Fam Pract. 1992 Nov. 35(5):524-8. [Medline].

  131. Yoo JH, Chung CS, Kang SS. Relation of plasma homocyst(e)ine to cerebral infarction and cerebral atherosclerosis. Stroke. 1998 Dec. 29(12):2478-83. [Medline].

Vitamin B-12–associated neurological diseases. Cobalamin and folate metabolism. TS = thymidylate synthase, DHFR = dihydrofolate reductase, SHMT = serine methyl-transferase.
Vitamin B-12–associated neurological diseases. Cobalamin deficiency leads to reduced adenosylcobalamin, which is required for production of succinyl-CoA. D-methylmalonyl-CoA is converted to methylmalonic acid.
Vitamin B-12–associated neurological diseases. Pernicious anemia. Characteristic lemon-yellow pallor with raw beef tongue lacking filiform papillae. Photo from Forbes and Jackson with permission.
Vitamin B-12–associated neurological diseases. Fluid attenuated inversion recovery (Flair) MRI sequence in a patient with cobalamin deficiency and neuropsychiatric manifestations. Discrete areas of hyperintensities are present in the corona radiata.
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.